Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
EHC vs USPH vs SEM vs ENSG vs ACHC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
EHC vs USPH vs SEM vs ENSG vs ACHC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $10.66B | $897M | $2.04B | $10.18B | $2.25B |
| Revenue (TTM) | $6.07B | $695M | $5.52B | $5.27B | $3.37B |
| Net Income (TTM) | $609M | $11M | $134M | $363M | $-1.11B |
| Gross Margin | 58.8% | 22.0% | 10.6% | 15.2% | 56.2% |
| Operating Margin | 16.8% | 12.2% | 5.8% | 8.5% | 11.7% |
| Forward P/E | 18.1x | 20.6x | 13.1x | 23.2x | 16.4x |
| Total Debt | $2.71B | $426M | $3.70B | $4.15B | $2.65B |
| Cash & Equiv. | $103M | $36M | $27M | $504M | $133M |
EHC vs USPH vs SEM vs ENSG vs ACHC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Encompass Health Co… (EHC) | 100 | 184.0 | +84.0% |
| U.S. Physical Thera… (USPH) | 100 | 79.6 | -20.4% |
| Select Medical Hold… (SEM) | 100 | 189.2 | +89.2% |
| The Ensign Group, I… (ENSG) | 100 | 398.7 | +298.7% |
| Acadia Healthcare C… (ACHC) | 100 | 85.5 | -14.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EHC vs USPH vs SEM vs ENSG vs ACHC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EHC carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 0.40, Low D/E 82.8%, current ratio 1.08x
- PEG 1.27 vs ENSG's 1.68
- Beta 0.40, yield 0.6%, current ratio 1.08x
- 10.0% margin vs ACHC's -32.8%
USPH ranks third and is worth considering specifically for income & stability.
- Dividend streak 5 yrs, beta 0.93, yield 3.1%
- 3.1% yield, 5-year raise streak, vs ENSG's 0.1%, (1 stock pays no dividend)
SEM is the clearest fit if your priority is value.
- Lower P/E (13.1x vs 16.4x)
ENSG is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
- 7.5% 10Y total return vs EHC's 252.2%
- 18.7% revenue growth vs ACHC's 5.0%
- +27.5% vs USPH's -14.3%
Among these 5 stocks, ACHC doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.7% revenue growth vs ACHC's 5.0% | |
| Value | Lower P/E (13.1x vs 16.4x) | |
| Quality / Margins | 10.0% margin vs ACHC's -32.8% | |
| Stability / Safety | Beta 0.40 vs USPH's 0.93 | |
| Dividends | 3.1% yield, 5-year raise streak, vs ENSG's 0.1%, (1 stock pays no dividend) | |
| Momentum (1Y) | +27.5% vs USPH's -14.3% | |
| Efficiency (ROA) | 8.7% ROA vs ACHC's -18.6%, ROIC 13.9% vs 5.9% |
EHC vs USPH vs SEM vs ENSG vs ACHC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EHC vs USPH vs SEM vs ENSG vs ACHC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
EHC leads in 2 of 6 categories
SEM leads 1 • ENSG leads 1 • USPH leads 0 • ACHC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
EHC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EHC is the larger business by revenue, generating $6.1B annually — 8.7x USPH's $695M. EHC is the more profitable business, keeping 10.0% of every revenue dollar as net income compared to ACHC's -32.8%. On growth, ENSG holds the edge at +18.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $6.1B | $695M | $5.5B | $5.3B | $3.4B |
| EBITDAEarnings before interest/tax | $1.4B | $107M | $465M | $558M | $588M |
| Net IncomeAfter-tax profit | $609M | $11M | $134M | $363M | -$1.1B |
| Free Cash FlowCash after capex | $172M | $67M | $117M | $406M | -$215M |
| Gross MarginGross profit ÷ Revenue | +58.8% | +22.0% | +10.6% | +15.2% | +56.2% |
| Operating MarginEBIT ÷ Revenue | +16.8% | +12.2% | +5.8% | +8.5% | +11.7% |
| Net MarginNet income ÷ Revenue | +10.0% | +1.5% | +2.4% | +6.9% | -32.8% |
| FCF MarginFCF ÷ Revenue | +2.8% | +9.6% | +2.1% | +7.7% | -6.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.0% | +7.7% | +5.0% | +18.4% | +7.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.6% | -115.0% | -18.2% | +21.9% | -49.8% |
Valuation Metrics
SEM leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 13.9x trailing earnings, SEM trades at a 66% valuation discount to USPH's 41.5x P/E. Adjusting for growth (PEG ratio), EHC offers better value at 1.36x vs ENSG's 2.16x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $10.7B | $897M | $2.0B | $10.2B | $2.3B |
| Enterprise ValueMkt cap + debt − cash | $13.3B | $1.3B | $5.7B | $13.8B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | 19.35x | 41.55x | 13.93x | 29.85x | -2.01x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.10x | 20.63x | 13.06x | 23.19x | 16.42x |
| PEG RatioP/E ÷ EPS growth rate | 1.36x | — | — | 2.16x | — |
| EV / EBITDAEnterprise value multiple | 9.61x | 12.52x | 12.04x | 25.71x | 8.27x |
| Price / SalesMarket cap ÷ Revenue | 1.80x | 1.15x | 0.37x | 2.01x | 0.68x |
| Price / BookPrice ÷ Book value/share | 3.34x | 1.16x | 1.00x | 4.59x | 1.04x |
| Price / FCFMarket cap ÷ FCF | 24.26x | 14.71x | 5.33x | 27.46x | — |
Profitability & Efficiency
EHC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
EHC delivers a 18.9% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $-41 for ACHC. USPH carries lower financial leverage with a 0.55x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x. On the Piotroski fundamental quality scale (0–9), EHC scores 9/9 vs ACHC's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +18.9% | +1.4% | +6.6% | +16.6% | -40.9% |
| ROA (TTM)Return on assets | +8.7% | +0.9% | +2.3% | +6.8% | -18.6% |
| ROICReturn on invested capital | +13.9% | +5.6% | +4.8% | +7.0% | +5.9% |
| ROCEReturn on capital employed | +17.6% | +7.6% | +7.0% | +10.2% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 9 | 5 | 5 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.83x | 0.55x | 1.82x | 1.86x | 1.24x |
| Net DebtTotal debt minus cash | $2.6B | $390M | $3.7B | $3.7B | $2.5B |
| Cash & Equiv.Liquid assets | $103M | $36M | $27M | $504M | $133M |
| Total DebtShort + long-term debt | $2.7B | $426M | $3.7B | $4.2B | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | 6.54x | 15.42x | 4.41x | 88.33x | -5.99x |
Total Returns (Dividends Reinvested)
ENSG leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ENSG five years ago would be worth $20,324 today (with dividends reinvested), compared to $3,823 for ACHC. Over the past 12 months, ENSG leads with a +27.5% total return vs USPH's -14.3%. The 3-year compound annual growth rate (CAGR) favors ENSG at 23.6% vs ACHC's -29.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.1% | -24.6% | +11.4% | +0.3% | +71.2% |
| 1-Year ReturnPast 12 months | -8.1% | -14.3% | +11.1% | +27.5% | +1.2% |
| 3-Year ReturnCumulative with dividends | +75.4% | -43.7% | +7.4% | +88.9% | -64.5% |
| 5-Year ReturnCumulative with dividends | +63.3% | -43.4% | -11.1% | +103.2% | -61.8% |
| 10-Year ReturnCumulative with dividends | +252.2% | +22.6% | +158.5% | +752.0% | -58.5% |
| CAGR (3Y)Annualised 3-year return | +20.6% | -17.4% | +2.4% | +23.6% | -29.2% |
Risk & Volatility
Evenly matched — EHC and SEM each lead in 1 of 2 comparable metrics.
Risk & Volatility
EHC is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than USPH's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEM currently trades 96.8% from its 52-week high vs USPH's 63.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.40x | 0.93x | 0.46x | 0.42x | 0.84x |
| 52-Week HighHighest price in past year | $127.99 | $93.50 | $16.99 | $218.00 | $30.20 |
| 52-Week LowLowest price in past year | $92.77 | $58.55 | $11.65 | $133.81 | $11.43 |
| % of 52W HighCurrent price vs 52-week peak | +83.7% | +63.1% | +96.8% | +80.0% | +81.0% |
| RSI (14)Momentum oscillator 0–100 | 53.6 | 46.1 | 60.9 | 23.3 | 46.2 |
| Avg Volume (50D)Average daily shares traded | 921K | 171K | 2.1M | 358K | 3.1M |
Analyst Outlook
Evenly matched — USPH and ENSG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: EHC as "Buy", USPH as "Buy", SEM as "Hold", ENSG as "Buy", ACHC as "Buy". Consensus price targets imply 72.9% upside for USPH (target: $102) vs -3.9% for ACHC (target: $24). For income investors, USPH offers the higher dividend yield at 3.06% vs ENSG's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $153.00 | $102.00 | $18.00 | $222.33 | $23.50 |
| # AnalystsCovering analysts | 26 | 12 | 13 | 13 | 25 |
| Dividend YieldAnnual dividend ÷ price | +0.6% | +3.1% | +1.5% | +0.1% | — |
| Dividend StreakConsecutive years of raises | 2 | 5 | 0 | 12 | 1 |
| Dividend / ShareAnnual DPS | $0.70 | $1.80 | $0.25 | $0.24 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.5% | +0.6% | +4.9% | +0.2% | +2.2% |
EHC leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SEM leads in 1 (Valuation Metrics). 2 tied.
EHC vs USPH vs SEM vs ENSG vs ACHC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EHC or USPH or SEM or ENSG or ACHC a better buy right now?
For growth investors, The Ensign Group, Inc.
(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus 5. 0% for Acadia Healthcare Company, Inc. (ACHC). Select Medical Holdings Corporation (SEM) offers the better valuation at 13. 9x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Encompass Health Corporation (EHC) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EHC or USPH or SEM or ENSG or ACHC?
On trailing P/E, Select Medical Holdings Corporation (SEM) is the cheapest at 13.
9x versus U. S. Physical Therapy, Inc. at 41. 5x. On forward P/E, Select Medical Holdings Corporation is actually cheaper at 13. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Encompass Health Corporation wins at 1. 27x versus The Ensign Group, Inc. 's 1. 68x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — EHC or USPH or SEM or ENSG or ACHC?
Over the past 5 years, The Ensign Group, Inc.
(ENSG) delivered a total return of +103. 2%, compared to -61. 8% for Acadia Healthcare Company, Inc. (ACHC). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus ACHC's -58. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EHC or USPH or SEM or ENSG or ACHC?
By beta (market sensitivity over 5 years), Encompass Health Corporation (EHC) is the lower-risk stock at 0.
40β versus U. S. Physical Therapy, Inc. 's 0. 93β — meaning USPH is approximately 130% more volatile than EHC relative to the S&P 500. On balance sheet safety, U. S. Physical Therapy, Inc. (USPH) carries a lower debt/equity ratio of 55% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — EHC or USPH or SEM or ENSG or ACHC?
By revenue growth (latest reported year), The Ensign Group, Inc.
(ENSG) is pulling ahead at 18. 7% versus 5. 0% for Acadia Healthcare Company, Inc. (ACHC). On earnings-per-share growth, the picture is similar: Encompass Health Corporation grew EPS 24. 2% year-over-year, compared to -537. 4% for Acadia Healthcare Company, Inc.. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EHC or USPH or SEM or ENSG or ACHC?
Encompass Health Corporation (EHC) is the more profitable company, earning 9.
5% net margin versus -33. 3% for Acadia Healthcare Company, Inc. — meaning it keeps 9. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EHC leads at 17. 7% versus 6. 1% for SEM. At the gross margin level — before operating expenses — EHC leads at 95. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EHC or USPH or SEM or ENSG or ACHC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Encompass Health Corporation (EHC) is the more undervalued stock at a PEG of 1. 27x versus The Ensign Group, Inc. 's 1. 68x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Select Medical Holdings Corporation (SEM) trades at 13. 1x forward P/E versus 23. 2x for The Ensign Group, Inc. — 10. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USPH: 72. 9% to $102. 00.
08Which pays a better dividend — EHC or USPH or SEM or ENSG or ACHC?
In this comparison, USPH (3.
1% yield), SEM (1. 5% yield), EHC (0. 6% yield), ENSG (0. 1% yield) pay a dividend. ACHC does not pay a meaningful dividend and should not be held primarily for income.
09Is EHC or USPH or SEM or ENSG or ACHC better for a retirement portfolio?
For long-horizon retirement investors, Encompass Health Corporation (EHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
40), 0. 6% yield, +252. 2% 10Y return). Both have compounded well over 10 years (EHC: +252. 2%, ACHC: -58. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EHC and USPH and SEM and ENSG and ACHC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EHC is a mid-cap quality compounder stock; USPH is a small-cap high-growth stock; SEM is a small-cap deep-value stock; ENSG is a mid-cap high-growth stock; ACHC is a small-cap quality compounder stock. EHC, USPH, SEM pay a dividend while ENSG, ACHC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.